Natsumi Nakamura1, Kenji Kishimoto2, Toshiaki Ishida3, Sayaka Nakamura3, Akihiro Tamura3, Aiko Kozaki3, Atsuro Saito3, Daiichiro Hasegawa3, Yoshiyuki Kosaka3. 1. Pediatric Emergency Department, Hyogo Prefectural Amagasaki General Medical Center, Higashi-Naniwacho 2-17-77, Amagasaki, 660-8550, Japan. 2. Department of Hematology & Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan. ken@yacht.ocn.ne.jp. 3. Department of Hematology & Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Abstract
The clinical characteristics, cause, and risk factors of sarcopenia are unclear in children. The aim of this study was to describe the course of and identify the factors related to muscle mass change during chemotherapy in children with neuroblastoma. A total of 24 consecutive patients aged below 18 years with newly diagnosed high-risk neuroblastoma between 2010 and 2018 in our hospital were enrolled in a case-series study. The psoas muscle index (PMI) was calculated as a parameter of muscle mass based on computer tomography (CT) images of the psoas muscle. PMIs were evaluated at 4 time points (TPs): TP1, at the diagnosis of neuroblastoma; TP2, after the first cycle of chemotherapy; TP3, after the third cycle of chemotherapy; and TP4, at the end of the induction chemotherapy. PMI recovery was defined as an increase in PMI between TP2 and TP4. The mean PMI decreased by 15% between TP1 and TP2 (TP1 7.09 ± 0.99 vs. TP2 6.01 ± 0.98, P < 0.001) and by 10% between TP1 and TP4 (TP1 7.09 vs. TP4 6.35, P = 0.004). PMI recovery between TP1 and TP2 was observed in 7 (29%) patients. The median age of patients with PMI recovery was significantly lower (2 vs. 4 years, P = 0.028), and the proportion of boys was significantly higher in patients with PMI recovery (100% vs. 41%, P = 0.017). Conclusion: This study demonstrated that prominent PMI reduction occurs during the early time of chemotherapy, and a younger age and male sex may be predictive factors for PMI recovery. What is Known: • Sarcopenia is a common disorder in elderly people. • Several causes and risk factors have been reported in adults. • Children with previous hematological malignancies have decreased physical activity. What is New: • Prominent muscle mass loss was observed early in children with high-risk neuroblastoma during chemotherapy. • Age and sex were found to be potentially associated with muscle mass recovery.
The clinical characteristics, cause, and risk factors of sarcopenia are unclear in children. The aim of this study was to describe the course of and identify the factors related to muscle mass change during chemotherapy in children with neuroblastoma. A total of 24 consecutive patients aged below 18 years with newly diagnosed high-risk neuroblastoma between 2010 and 2018 in our hospital were enrolled in a case-series study. The psoas muscle index (PMI) was calculated as a parameter of muscle mass based on computer tomography (CT) images of the psoas muscle. PMIs were evaluated at 4 time points (TPs): TP1, at the diagnosis of neuroblastoma; TP2, after the first cycle of chemotherapy; TP3, after the third cycle of chemotherapy; and TP4, at the end of the induction chemotherapy. PMI recovery was defined as an increase in PMI between TP2 and TP4. The mean PMI decreased by 15% between TP1 and TP2 (TP1 7.09 ± 0.99 vs. TP2 6.01 ± 0.98, P < 0.001) and by 10% between TP1 and TP4 (TP1 7.09 vs. TP4 6.35, P = 0.004). PMI recovery between TP1 and TP2 was observed in 7 (29%) patients. The median age of patients with PMI recovery was significantly lower (2 vs. 4 years, P = 0.028), and the proportion of boys was significantly higher in patients with PMI recovery (100% vs. 41%, P = 0.017). Conclusion: This study demonstrated that prominent PMI reduction occurs during the early time of chemotherapy, and a younger age and male sex may be predictive factors for PMI recovery. What is Known: • Sarcopenia is a common disorder in elderly people. • Several causes and risk factors have been reported in adults. • Children with previous hematological malignancies have decreased physical activity. What is New: • Prominent muscle mass loss was observed early in children with high-risk neuroblastoma during chemotherapy. • Age and sex were found to be potentially associated with muscle mass recovery.
Entities:
Keywords:
Case series; Chemotherapy; Muscle mass; Neuroblastoma; Sarcopenia
Authors: H A Bischoff-Ferrari; J E Orav; J A Kanis; R Rizzoli; M Schlögl; H B Staehelin; W C Willett; B Dawson-Hughes Journal: Osteoporos Int Date: 2015-06-12 Impact factor: 4.507
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: G B Stene; J L Helbostad; T R Balstad; I I Riphagen; S Kaasa; L M Oldervoll Journal: Crit Rev Oncol Hematol Date: 2013-08-09 Impact factor: 6.312
Authors: Katja I Braam; Elisabeth M van Dijk-Lokkart; Gertjan J L Kaspers; Tim Takken; Jaap Huisman; Laurien M Buffart; Marc B Bierings; Johannes H M Merks; Marry M van den Heuvel-Eibrink; Margreet A Veening; Eline van Dulmen-den Broeder Journal: BMC Cancer Date: 2018-12-27 Impact factor: 4.430
Authors: Antonino Bianco; Antonino Patti; Ewan Thomas; Romilda Palma; Maria Cristina Maggio; Antonio Paoli; Antonio Palma Journal: Cancer Med Date: 2014-02-12 Impact factor: 4.452
Authors: Alfonso J Cruz-Jentoft; Francesco Landi; Stéphane M Schneider; Clemente Zúñiga; Hidenori Arai; Yves Boirie; Liang-Kung Chen; Roger A Fielding; Finbarr C Martin; Jean-Pierre Michel; Cornel Sieber; Jeffrey R Stout; Stephanie A Studenski; Bruno Vellas; Jean Woo; Mauro Zamboni; Tommy Cederholm Journal: Age Ageing Date: 2014-09-21 Impact factor: 10.668